Non-Hodgkin Lymphoma (Oncology) - Drugs in Development, 2021

October 2021 | 4641 pages | ID: NAC2F0843D4BEN
Global Markets Direct

Abstracts

Non-Hodgkin Lymphoma (Oncology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Drugs In Development, 2021, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 23, 2, 44, 230, 239, 14, 28, 210, 35 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 33, 47, 3, 39, 5 and 1 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Non-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Non-Hodgkin Lymphoma, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, 2021
Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, 2021
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, 2021
Non-Hodgkin Lymphoma - Pipeline by Abologix Sarl, 2021
Non-Hodgkin Lymphoma - Pipeline by Acerta Pharma BV, 2021
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Actinobac Biomed Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Adagene Suzhou Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, 2021
Non-Hodgkin Lymphoma - Pipeline by Adicet Bio Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Adienne Pharma & Biotech SA, 2021
Non-Hodgkin Lymphoma - Pipeline by Adlai Nortye Biopharma Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Advenchen Laboratories LLC, 2021
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, 2021
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, 2021
Non-Hodgkin Lymphoma - Pipeline by AGC Biologics SpA, 2021
Non-Hodgkin Lymphoma - Pipeline by AI Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Akeso Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Aleta Biotherapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Alexion Pharmaceuticals Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Alfasigma SpA, 2021
Non-Hodgkin Lymphoma - Pipeline by Allogene Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Alphamab Oncology, 2021
Non-Hodgkin Lymphoma - Pipeline by Alpine Immune Sciences Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by ALX Oncology Holdings Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Anew Oncology Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, 2021
Non-Hodgkin Lymphoma - Pipeline by Angiocrine Bioscience Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Anhorn Medicines Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Antengene Corp Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by AP Biosciences Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Apollomics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Apotex Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Applied Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Aprea Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Archigen Biotech Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Arcus Biosciences Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Ardan Pharma, 2021
Non-Hodgkin Lymphoma - Pipeline by Argenx SE, 2021
Non-Hodgkin Lymphoma - Pipeline by Ascentage Pharma Group International, 2021
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, 2021
Non-Hodgkin Lymphoma - Pipeline by AUM Biosciences Pte Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Autolus Therapeutics Plc, 2021
Non-Hodgkin Lymphoma - Pipeline by Avalon GloboCare Corp, 2021
Non-Hodgkin Lymphoma - Pipeline by Avesthagen Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by AVM Biotechnology LLC, 2021
Non-Hodgkin Lymphoma - Pipeline by AzarGen Biotechnologies (Pty) Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by BAKX Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Bantam Pharmaceutical LLC, 2021
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, 2021
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Beijing Cytoheal Biotech Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Beijing Gaobo Biotechnology Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Beijing GD Initiative Cell Therapy Technology Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Celularity Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Elicera Therapeutics AB, 2021
Non-Hodgkin Lymphoma - Pipeline by Emmaus Life Sciences Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Enterome Bioscience SA, 2021
Non-Hodgkin Lymphoma - Pipeline by Epidestiny Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Epizyme Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by ERYTECH Pharma SA, 2021
Non-Hodgkin Lymphoma - Pipeline by Esanex Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Eternity Bioscience Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Eucure (Beijing) Biopharma Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Eureka Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Eutilex Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Evive Biotech, 2021
Non-Hodgkin Lymphoma - Pipeline by Evotec SE, 2021
Non-Hodgkin Lymphoma - Pipeline by Excelmab Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Magenta Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by ManysmarT Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Marino Biotechnology Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Marker Therapeutics Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Meabco AS, 2021
Non-Hodgkin Lymphoma - Pipeline by MedC Biopharma Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Medinet Co Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by MediSix Therapeutics Pte Ltd, 2021
Non-Hodgkin Lymphoma - Pipeline by Meditope Biosciences Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by Medivir AB, 2021
Non-Hodgkin Lymphoma - Pipeline by MedPacto Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, 2021
Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, 2021
Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Non-Hodgkin Lymphoma, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021